Clinical Trial Update: Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a GABA transaminase inhibitor to relieve obesity-induced hyperinsulinemia and insulin resistance has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glucose Intolerance
• Hyperinsulinemia
• Hypertension
• Insulin Resistance
• Obesity

Drugs mentioned

• GABA Transaminase Inhibitor (unspecified)

Snippet

Sponsor: University of Arizona | Conditions: Hyperinsulinism, Insulin Resistance | Phase 2 | Status: WITHDRAWN